J Korean Radiol Soc.
1994 Jul;31(1):49-53.
Combined Effect of Angioinfarction with Immunotherapy in Patients with Stage IV Renal Cell Carcinoma
Abstract
- PURPOSE
To assess the combined effectiveness of angioinfarction and immunotherapy for improving survival in patients with stage IV renal cell carcinoma.
MATERIALS AND METHODS
During the past 3 years, 13 patients of stage IV renal cell carcinoma were treated with angioinfarction and immunotherapy. Angioinfarction was performed on these 13 patients using absolute ethanol and occlusive baloon catheter. After angioinfarction, Interferon alpha was used for immunotherapy. For our analysis, 12 control patients of stage IV renal cell carcinoma without treatment were included in the study. Survival has been calculated according to the Kaplan and Meier method.
RESULTS
The 1 year survival rate and median survival time in patients treated with angioinfarction and immunotherapy, were 46% and 13 months and in patients without treatment, 16% and 4 months, respectively.
CONCLUSION
The combined treatment of angioinfarction and immunotherapy is of considerable value for improving survival in patients with stage IV renal cell carcinoma
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical Effect of Renal Angioinfarction in Renal Cell Carcinoma
- The Efficacy of Arterial Embolization in Patients with a Renal Cell Carcinoma
- Renal Cell Carcinoma-Angioinfarction and Adjunctive Nephrectomy
- A case of renal transitional cell carcinoma associated with synchronous contralateral renal cell carcinoma
- Three Cases of Childhood Renal Cell Carcinoma Including 2 Cases with Systemic Immunotherapy
